14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RGNX vs CRVS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Corvus Pharmaceuticals, Inc. (CRVS) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin), whereas CRVS carries 34.3/100 (SELL) at $10.63 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. CRVS 34.3/100 SELL), CRVS captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -120.4% operating margin) and revenue trajectory (+0.0% vs. -69.2% YoY).
Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile CRVS is in a Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RGNX vs CRVS. Trailing 12-month operating profitability (RGNX -120.4% vs CRVS 0.0%) and valuation multiples (RGNX N/M vs CRVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $895.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RGNX vs CRVS Key Questions & Quantitative Answers
As of Nov 16, 2026, Corvus Pharmaceuticals, Inc. (CRVS) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin), whereas CRVS carries 34.3/100 (SELL) at $10.63 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. CRVS 34.3/100 SELL), CRVS captures the overall institutional head-to-head verdict (7–1 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -120.4% operating margin) and revenue trajectory (+0.0% vs. -69.2% YoY). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile CRVS is in a Breakdown options structure phase (RSI 48.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRVS leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with CRVS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, RGNX generates $154M in USD-normalized revenue versus N/A for CRVS. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRVS.
RGNX screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas CRVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus CRVS (-45.9% ROE) capital efficiency.
In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk). By comparison, CRVS carries 79.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.87β · 71% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.